Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
Walid Shalata, Sarah Weissmann, Sapir Itzhaki Gabay, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5451-5451
Open Access | Times Cited: 23

Showing 23 citing articles:

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 67
Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience
Walid Shalata, Jeremy Zolnoorian, Gabrielle Migliozzi, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5938-5938
Open Access | Times Cited: 14
Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
Martina Merli, Martina Accorinti, Maurizio Romagnuolo, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 12
An Adverse Double-Hit by Pembrolizumab: A Case Report of Bullous Pemphigoid and Pneumonitis
Christodoulos Chatzigrigoriadis, Prodromos Avramidis, Christos Davoulos, et al.
Journal of Medical Cases (2025) Vol. 16, Iss. 2, pp. 69-76
Open Access
Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis
Jasper N. Pruessmann, Wiebke Pruessmann, Christian D. Sadik
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025)
Open Access
A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab
Ana B. Rossi, Donatella Brancorsini, Helena Gioacchini, et al.
Skin Health and Disease (2025) Vol. 5, Iss. 1, pp. 70-74
Open Access
Remote presentation of nivolumab-induced bullous pemphigoid in hepatocellular carcinoma
Ashley Yoo, Joyce Chen, Vivek Parameswara Sarma, et al.
BMJ Case Reports (2025) Vol. 18, Iss. 4, pp. e263285-e263285
Closed Access
Forschung für die Praxis: Bullöse Autoimmundermatosen unter Immuncheckpoint‐Inhibitoren
Jasper N. Pruessmann, Wiebke Prüßmann, Christian D. Sadik
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2025) Vol. 23, Iss. 4, pp. 441-446
Open Access
Unexpected Adverse Events of Immune Checkpoint Inhibitors
Walid Shalata, Alexander Yakobson, Aharon Y. Cohen, et al.
Life (2023) Vol. 13, Iss. 8, pp. 1657-1657
Open Access | Times Cited: 10
Immune Checkpoint Inhibitors in Cancer Therapy—How Can We Improve Clinical Benefits?
Constantin N. Baxevanis
Cancers (2023) Vol. 15, Iss. 3, pp. 881-881
Open Access | Times Cited: 9
Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid
Jianglin Wang, Xin Hu, Wei Jiang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
Ting Cao, Xuyang Zhou, Xingbiao Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
Keren Rouvinov, Gal Mazor, Ella Kozlener, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 11, pp. 1623-1623
Open Access | Times Cited: 7
Perimyocarditis Associated with Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
Walid Shalata, Rachel Steckbeck, Amjad Abu Salman, et al.
Medicina (2024) Vol. 60, Iss. 2, pp. 224-224
Open Access | Times Cited: 2
Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
Walid Shalata, Alexander Yakobson, Yulia Dudnik, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2438-2438
Open Access | Times Cited: 6
Carpal Tunnel Syndrome Associated with Immune Checkpoint Inhibitors
Alexander Yakobson, Keren Rouvinov, Aharon Y. Cohen, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 9, pp. 1340-1340
Open Access | Times Cited: 4
Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review
Walid Shalata, Zoé Gabrielle Attal, Rajeh Shhadi, et al.
Medicina (2023) Vol. 59, Iss. 11, pp. 1946-1946
Open Access | Times Cited: 4
The possible and intriguing relationship between bullous pemphigoid and melanoma: speculations on significance and clinical relevance
Filomena Russo, Anna Pira, Feliciana Mariotti, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
Alexander Yakobson, Ala Eddin Neime, Omar Abu Saleh, et al.
Clinics and Practice (2023) Vol. 13, Iss. 5, pp. 1082-1089
Open Access | Times Cited: 2
Immune checkpoint inhibitor‐associated bullous pemphigoid: A retrospective and real‐world study based on the United States Food and Drug Administration adverse event reporting system
Haowen Tan, Xiubi Chen, Ying Chen, et al.
The Journal of Dermatology (2024)
Closed Access
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
Abdulaziz M. Eshaq, Thomas W. Flanagan, Anass Abbad, et al.
International Journal of Molecular Sciences (2024) Vol. 26, Iss. 1, pp. 88-88
Open Access
Refractory bullous pemphigoid during treatment with pembrolizumab in the first-line treatment of advanced non-small cell lung cancer
Renata Olech, Monika Rychlik-Grabowska, Sławomir Mańdziuk
Forum Dermatologicum (2024)
Open Access
Antineoplastics

Reactions Weekly (2023) Vol. 1980, Iss. 1, pp. 47-47
Closed Access
Page 1

Scroll to top